Endocare Cryocare
This article was originally published in The Gray Sheet
Executive Summary
Minimally-invasive cryosurgical system gains 510(k) clearance for "keyhole" thoracoscopic cardiac tissue ablation procedures to treat arrhythmias. The clearance opens the door for "a new generation of devices currently under development that treat certain cardiac conditions in a less invasive fashion" under a September 2001 strategic alliance with CryoCath Technologies (1"The Gray Sheet" Oct. 1, 2001, p. 30)...
You may also be interested in...
Cryoablation Or Brachytherapy? Endocare Promotes Prostate First-Line Option
Endocare is hoping that the results of an eight-year 590-patient registry study will convince more urologists to use cryoablation as an alternative to brachytherapy for first-line treatment of prostate cancer
CryoCath/Endocare Deal Aimed At Minimally Invasive Cardiac Surgery Market
CryoCath anticipates that its five-year exclusive global supply and market access agreement with Endocare will allow for the development of a cryoablation device that can be used in keyhole surgery.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.